Minireviews
Copyright ©The Author(s) 2017.
World J Cardiol. Jul 26, 2017; 9(7): 594-599
Published online Jul 26, 2017. doi: 10.4330/wjc.v9.i7.594
Table 1 Overview of drugs targeting the neprilysin pathways and its pathways
DrugMechanismClinical trials and yearResults on HF symptoms
NestirideIncreasing natriuretic peptide activityVMAC, 2000[20] PRECEDENT, 2002[21] ASCENT-HF, 2009[22]Improved BP and dyspnea Less cardiac arrhythmias More hypotension
CandoxatrilNPiSingle-centered investigation with only a limited number of patients[23-25]More exercise tolerance Increase in vascular resistance
OmapatrilatNPiIMPRESS, 2000[26] OVERTURE, 2002[27] OCTAVE, 2004[28]More exercise tolerance Increase in angioedema Reduction in BP Lower mortality
LCZ696NPiPARAMOUNT, 2012[29] PARADIGM, 2014[30,31] PARAGON, ongoing[32]Reduction in BP Improved ejection fraction Lower mortality No change in angioedema